

The Innovation Oncology: An international journal of cancer science

Zhihao Lu² and Lin Shen^{1,*}

¹State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Department of GI Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China

²Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China

*Correspondence: shenlin@bjmu.edu.cn

Received: February 3, 2026; Accepted: April 21, 2026; Published Online: April 24, 2026; <https://doi.org/10.59717/j.xinn-oncol.2026.100001>

© 2026 The Author(s). This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>).

Citation: Lu Z. and Shen L. (2026). The Innovation Oncology: An international journal of cancer science. *The Innovation Oncology* 1:100001.

CONVERGING DISCIPLINES, TRANSFORMING THE FUTURE

The history of our fight against cancer shows how our ways of thinking changed, from Hippocrates's observations to discoveries made with microscopes, and it reaches the molecular biology revolution in the twentieth century. Scientists have learned more about the genetic basis of cancer. This has led to advances in targeted therapies and immunotherapy. I have worked in gastrointestinal oncology for more than thirty years. Over time I see a clear problem. Basic research gives useful results, but moving them into treatments that help patients is still hard. Tumor heterogeneity, drug resistance,

treatment-related toxicities, and predictive efficacy are key issues. To solve them, we need teams from different fields.

This realization led my colleagues and me to launch **The Innovation Oncology**. I think the way to overcome these barriers is to build a new approach that focuses on real clinical problems. This means breaking silos and mixing ideas and tools from AI, engineering, data science, and other fields with biological research. When doctors set clear clinical definitions, scientists share mechanistic insights, and engineers make new solutions, we can shorten the path from clinical issues to patient benefit.



This journal aims to create a top platform that tackles important clinical needs by bringing together experts from different fields, especially for real-world use. As an important part of The Innovation family in health and life sciences, we will focus on research that points to future directions in oncology.

We will focus on studies that come from real problems doctors face in clinics and try to answer important questions about diagnosis and treatment. The journal especially welcomes research that creates and uses new technologies for accurate prediction and monitoring. Examples include exploring how multi-omics technologies can predict immunotherapy efficacy and drug resistance; developing non-invasive methods for monitoring tumor evolution

and treatment responses; and enhancing traditional therapies by intervening in the tumor microenvironment.

We urge researchers to introduce cutting-edge technologies to address the complexities of oncology. This includes using artificial intelligence to find useful information in clinical imaging and genomic data. It also includes building personalized drug sensitivity tests with organoids. Another line is to design smart drug delivery based on nanotechnology. And researchers can push CAR-T cell therapy by combining immunology, gene editing, and synthetic biology. These new processes range from target selection to improving clinical efficacy. They show the benefits of interdisciplinary collaboration.

The real value of innovation is how much it can improve patient outcomes. **The Innovation Oncology** focuses on the whole path of translational medicine. It accepts studies that start with understanding mechanisms and developing proof-of-concept technologies, and go all the way to early-phase and late-stage clinical trials. These trials are judged using real-world data. We want to present research that pushes scientific boundaries and also shows real impact on how doctors diagnose and treat patients, which can change patient care. Our work goes beyond innovation. We make sure ideas become practical applications that can change treatment approaches.

As the Editor-in-Chief, I invite clinical oncology experts, basic research scientists, and colleagues in engineering and data who share our goal of overcoming cancer. Please submit your solid, new, and clinically oriented work to our journal. Let us connect through **The Innovation Oncology**. We can collaborate to face challenges and work together to turn scientific possibilities into hope for cancer patients.

AUTHOR CONTRIBUTIONS

All authors contributed to the manuscript and approved the final version.